Premium
P1‐386: COGNITIVE RECOVERY BY HBF BRAIN FOOD
Author(s) -
Hasegawa Tohru,
Wakayama Toshibumi,
Tabira Takeshi
Publication year - 2014
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2014.05.628
Subject(s) - cognitive impairment , cognition , stage (stratigraphy) , medicine , ingestion , peripheral blood , cognitive decline , psychiatry , dementia , biology , disease , paleontology
Background:Alzheimer Disease (AD) is associated with synapse loss. The medical food Souvenaid 1 contains Fortasyn 1 Connect, a combination of nutrients designed to enhance synapse formation and function in AD. Two earlier studies demonstrated memory improvement in mild AD dementia patients after Souvenaid intervention for 12 and 24 weeks.The 24-week study also showed effects on brain network organisation measured with electroencephalography (EEG), which strengthens the hypothesis that Souvenaid affects synaptic formation and function. To provide further insight into Souvenaid’s hypothesised mode of action, the current NL-ENIGMA study 2 explores brain glucose metabolism in mild cognitive impairment (MCI) and mild dementia due to AD, using Positron Emission Tomography with 18 F-fluorodeoxyglucose (18 F-FDG-PET) as indicator for synapse function. The rationale and study design of the study will be presented. 1 Souvenaid and Fortasyn are registered trademarks of N.V. Nutricia.2 Funded by NWO NIHC project, N 057-13-003. Methods: The NLENIGMA study is an exploratory, randomised controlled study. A total of 40 drug-na€ıve subjects with MCI or mild dementia due to AD (MMSE 20 and presence of amyloid burden) will be 1:1 randomised to receive either Souvenaid (containing Fortasyn Connect) or an iso-caloric control product (without Fortasyn Connect) for a 24-week period. At baseline and after 24 weeks, participants will undergo quantitative 18 F-FDG-PET imaging including arterial sampling. To collect further information on the mode of action of Souvenaid, additional assessments include relative and absolute 18 F-FDG-PET imaging, magnetic resonance imaging (MRI) (i.e. structural MRI, resting-state functional MRI, diffusion tensor imaging and arterial spin labelling), cerebrospinal fluid (CSF) and the assessment of blood parameters. Results: The study will start in May 2014. Conclusions: The NL-ENIGMA study will explore the effect of Souvenaid on brain glucose metabolism in early AD using 18 F-FDG-PET imaging.